Abstract
The recently identified hepatitis C virus (HCV)1 is responsible for almost 90% of cases of chronic post-transfusion non-A, non-B hepatitis and for more than 70% of sporadic cases2. Acute NANB hepatitis becomes chronic in 50% of cases3 and 20–30% of them progress to cirrhosis4.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Q.L. Choo, G. Kuo, A.J. Weiner, L.R. Overby, D.W. Bradley, M. Houghton, Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome, Science 244: 359 (1989).
D.Sansonno, F. Dammacco, Antibodies to hepatitis C virus in non-A, non-B post-transfusion and cryptogenic chronic liver disease, Lancet ii: 798 (1989).
H.J. Alter, Transfusion-associated non-A, non-B hepatitis: the first decade, in: “Viral hepatitis and liver disease”, A.J. Zuckerman, ed, A.R. Liss, New York (1988).
R.L. Koretz, O. Stone, M. Mousa, G.L. Gitnik, Non-A, non-B post-transfusion hepatitis. A decade later, Gastroenterology 88: 1251 (1985).
W.H. Caselmann, J. Eisenburg, P.H. Hofschneider, R. Koshy, ß and γ-interferon in chronic active hepatitis B. A pilot trial of short term combination therapies, Gastroenterology 96: 449 (1989).
A. Biliau, The clinical application of fibroblast interferon. An overview, Med Oncol & Tumor Pharmacother 1: 87 (1984).
K. Ohnishi, F. Nomura, S. Lida, Treatment of post-transfusion non-A, non-B acute and chronic hepatitis with human fibroblast 6-interferon: A preliminary report, Am J Gastroenterol 84: 596 (1989).
K. Chayama, S. Saiton, Y. Arase, K. Ikeda, T. Matsumoto, Y. Sakai, M. Kobayashi, M. Unakami, T. Morinaga, H. Kumada, Effect of interferon administration on serum hapatitis C virus RNA in patients with chronic hepatitis C, Hepatology 13: 1040 (1991).
D.M. Campoli-Richards, E.M. Sorkin, R.C. Heel, Inosine pranobex: a preliminary review of its pharmacodynamics and pharmacokinetics properties, and therapeutic efficacy, Drugs 32: 383 (1986).
W. Prohasca, K. Kleesiek, Treatment of chronic hepatitis C with inosine pranobex, Lancet 338: 390 (1991).
D. Sansonno, P. Detomaso, M.A. Papanice, G. Fiore, G. Bufano, O.G. Manghisi, Correlation between hepatitis B virus deoxyribonucleic acid and receptors for polymerized human albumine in HBV chronic infection, Digestion 37: 206 (1987).
G.L. Davis, L.A. Balart, E.R. Schiff, K. Lindsay, H.C. Bodenheimer, R.P. Perrillo, W. Carey, I.M. Jacobson, J. Payne, J.L. Dienstag, D.H. Vanthiel, C. Tamburro, J.Lefkowitch, J. Albrecht, C. Meschievitz, T.J. Ortego, A.Gibas, Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 321: 1501 (1989).
X. Causse, H. Godinot, M. Chevallier, P. Chossegros, F. Zoulin, D. Ouzan, J-P. Heyraud, T. Fontanges, J. Albrecht, C. Meschievitz, C. Trepo, Comparison of 1 or 3 MU of Interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101: 497 (1991).
D. Sansonno, V. Cornacchiulo, P. Gatti, F. Dammacco, Circulating levels and liver tissue distribution of intercellular adhesion molecule-1 during ß-interferon therapy of hepatitis C virus-associated chronic active disease, Int J Clin Lab Res 22: 100 (1992).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sansonno, D., Azzolini, C., Dammacco, F. (1993). Treatment of Hepatitis C Virus-Associated Chronic Liver Disease with ß-Interferon and Inosine Pranobex: Combination Schedule vs Monotherapies. In: Garaci, E., Goldstein, A.L. (eds) Combination Therapies 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2964-4_25
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2964-4_25
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6289-0
Online ISBN: 978-1-4615-2964-4
eBook Packages: Springer Book Archive